One of the great mysteries that has long bewildered cardiologists is why as many people with normal cholesterol levels suffer from heart disease and sudden cardiac death as do those with elevated cholesterol. Building on technology developed at the Ernest Orlando Lawrence Berkeley National Laboratory, Berkeley HeartLab has developed a battery of proprietary diagnostic tests that reveal cholesterol abnormalities that go beyond conventional HDL and LDL analysis. Berkeley HeartLab was founded as a cardiovascular reference lab that had a unique diagnostic approach but floundered largely because of the company's inability to convince cardiologists of the benefits of this new method over traditional cholesterol tests. A classic example of a re-start, new management appears to have unearthed the value in the company's proprietary testing program by recognizing the advantage in marketing Berkeley HeartLab's product as a cardiovascular diagnostic planning and disease management tool powered by web-enabled e-health technology.
by Stephen Levin
Between the joyous success of over-subscribed IPOs and disappointing failure of failed clinical trials there lies a kind of corporate...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.
Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.
An interactive look at pharma, medtech and diagnostics deals made during May 2025. Data courtesy of Biomedtracker.
Flagship Pioneering senior partner Raj Panjabi discusses shifting health care from reactive treatment to AI-powered prediction and prevention of disease before symptoms emerge.
Namrata Saroj, chief business officer of Ocular Therapeutix, is highly respected in the retina community for her contributions to drug development. She talked to In Vivo about her journey in ophthalmology, leadership philosophy and the importance of authenticity in a close-knit specialty.
